Bandırma Onyedi Eylül Üniversitesi Sağlık Bilimleri ve Araştırmaları Dergisi 2687-2145 Bandırma Onyedi Eylül Üniversitesi 10.46413/boneyusbad.1415742 Nutritional Science Beslenme Bilimi Potential Protective Effects of Epigallocatechin Gallate (EGCG) on Parkinson's Disease Pathogenesis Epigallokateşin Gallatın (EGCG) Parkinson Hastalığı Patogenezinde Potansiyel Koruyucu Etkileri https://orcid.org/0000-0003-3350-4777 Yıldız Elif ANKARA MEDİPOL ÜNİVERSİTESİ, SAĞLIK BİLİMLERİ FAKÜLTESİ https://orcid.org/0000-0001-8788-2242 Yıldırım İlknur Gökçe ANKARA MEDİPOL ÜNİVERSİTESİ, SAĞLIK BİLİMLERİ FAKÜLTESİ 08 22 2024 6 2 427 435 01 06 2024 05 16 2024 Copyright © 2019, Bandırma Onyedi Eylül Üniversitesi Sağlık Bilimleri ve Araştırmaları Dergisi 2019 Bandırma Onyedi Eylül Üniversitesi Sağlık Bilimleri ve Araştırmaları Dergisi

The aim of this review is to examine the protective effects of epigallocatechin gallate on the pathogenesis of Parkinson's disease. Epidemiological studies conducted in recent years emphasize that Parkinson's disease has increased and has doubled in the last 25 years. Therefore, it becomes important to evaluate the factors that may affect the pathogenesis of the disease. Studies have found that factors such as oxidative stress, inflammation and abnormal aggregation of α-synuclein protein occurring in the body play a role in the pathogenesis of Parkinson's. Epigallocatechin gallate, one of the tea components, may be related to the pathogenesis of Parkinson's with its anti-inflammatory properties and protective effect against oxidative stress and α-synuclein-induced damage. As a result, clinical studies on the protective effect of epigallocatechin gallate on Parkinson's disease are scarce. In future research, the effectiveness of epigallocatechin gallate on Parkinson's disease can be evaluated with more evidence-based clinical studies.

Bu derlemenin amacı, epigallokateşin gallatın Parkinson hastalığı patogenezi üzerindeki koruyucu etkilerini incelemektir. Son yıllarda yapılan epidemiyolojik çalışmalarda Parkinson hastalığının artış gösterdiği ve son 25 yılda ikiye katlandığı vurgulanmaktadır. Bundan dolayı hastalığın patogenezine etki edebilen faktörleri değerlendirmek önem kazanmaktadır. Yapılan çalışmalarda vücutta meydana gelen oksidatif stres, inflamasyon ve α-sinüklein proteinin anormal agregasyonu gibi faktörlerin Parkinson’un patogenezinde rol oynadığı saptanmıştır. Çay bileşenlerinden epigallokateşin gallat antiinflamatuar özelliği, oksidatif stres ve α-sinüklein kaynaklı hasara karşı koruyucu etkisi ile Parkinson’un patogeneziyle ilişkili olabilmektedir. Sonuç olarak, epigallokateşin gallatın Parkinson üzerindeki koruyucu etkisine yönelik klinik araştırmalar azdır. Gelecek araştırmalarda daha fazla kanıta dayalı klinik çalışmalarla epigallokateşin gallatın Parkinson üzerindeki etkinliği değerlendirilebilir.

 Parkinson hastalığı Epigallokateşin gallat (EGCG) İnflamasyon Oksidatif stres Alfa-sinüklein Parkinson disease Epigallocatechin gallate (EGCG) Inflamation Oxidative stress Alpha-synuclein Armstrong, M. J., Okun, M. S. (2020). Diagnosis and treatment of Parkinson disease: A review. Jama, 323(6), 548-560. doi: 10.1001/jama.2019.22360 Barrera, G., Pizzimenti, S., Daga, M., Dianzani, C., Arcaro, A., Cetrangolo, G. P., … Gentile, F. (2018). Lipid peroxidation-derived aldehydes, 4-hydroxynonenal and malondialdehyde in aging-related disorders. Antioxidants (Basel, Switzerland), 7(8), 102. doi: 10.3390/antiox7080102 Bazyar, H., Hosseini, S. A., Saradar, S., Mombaini, D., Allivand, M., Labibzadeh, M., … Alipour, M. (2020). Effects of epigallocatechin-3-gallate of Camellia sinensis leaves on blood pressure, lipid profile, atherogenic index of plasma and some inflammatory and antioxidant markers in type 2 diabetes mellitus patients: a clinical trial. Journal of Complementary & Integrative Medicine, 18(2), 405–411. doi: 10.1515/jcim-2020-0090 Berg, D., Postuma, R. B., Adler, C. H., Bloem, B. R., Chan, P., Dubois, B., … Deuschl, G. (2015). MDS research criteria for prodromal Parkinson's disease. Movement Disorders: Official Journal of the Movement Disorder Society, 30(12), 1600–1611. doi: 10.1002/mds.26431 Błaszczyk, J. W. (1998). Motor deficiency in Parkinson's disease. Acta Neurobiologiae Experimentalis, 58(1), 79-93. doi: 10.55782/ane-1998-1262 Block, M. L., Zecca, L., Hong, J. S. (2007). Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nature Reviews. Neuroscience, 8(1), 57–69. doi: 10.1038/nrn2038 Bloem, B. R, Okun, M. S., Klein, C. (2021). Parkinson's disease. Lancet (London, England), 397(10291), 2284–2303. doi: 10.1016/S0140-6736(21)00218-X Braicu, C., Ladomery, M. R., Chedea, V. S., Irimie, A., Berindan-Neagoe, I. (2013). The relationship between the structure and biological actions of green tea catechins. Food Chemistry, 141(3), 3282-3289. doi: 10.1016/j.foodchem.2013.05.122 Brochard, V., Combadière, B., Prigent, A., Laouar, Y., Perrin, A., Beray-Berthat, V., ... Hunot, S. (2008). Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. The Journal of Clinical Investigation, 119(1). doi: 10.1172/JCI36470 Byun, E. B., Kim, W. S., Sung, N. Y., Byun, E. H. (2018). Epigallocatechin-3-gallate regulates anti-inflammatory action through 67-kDa laminin receptor-mediated tollip signaling induction in lipopolysaccharide-stimulated human intestinal epithelial cells. Cellular Physiology and Biochemistry, 46(5), 2072-2081. doi: 10.1159/000489447 Cabrera, C., Artacho, R., Giménez, R. (2006). Beneficial effects of green tea—a review. Journal of the American College of Nutrition, 25(2), 79–99. doi: 10.1080/07315724.2006.10719518. Chan, P., Qin, Z., Zheng, Z., Zhang, L. (2009). A randomized, double-blind, placebo-controlled, delayed start study to assess safty, tolerability and efflcacy of green tea polyphenols in Parkinson's disease (P2.204). Parkinsonism Related Disorders, 15, 145. doi: 10.1016/S1353-8020(09)70555-3 Dickson, D. W. (2012). Parkinson’s disease and parkinsonism: neuropathology. Cold Spring Harbor Perspectives in Medicine, 2(8), a009258. doi: 10.1101/cshperspect.a009258 Dorsey, E., Sherer, T., Okun, M. S., Bloem, B. R. (2018). The emerging evidence of the Parkinson pandemic. Journal of Parkinson's Disease, 8(s1), 3-8. doi: 10.3233/JPD-181474 Elsworth, J. D. (2020). Parkinson's disease treatment: past, present, and future. Journal of Neural Transmission (Vienna, Austria: 1996), 127(5), 785–791. doi: 10.1007/s00702-020-02167-1 Fernandes, L., Messias, B., Pereira-Neves, A., Azevedo, E. P., Araújo, J., Foguel, D., … Palhano, F. L. (2020). Green tea polyphenol microparticles based on the oxidative coupling of EGCG inhibit amyloid aggregation/cytotoxicity and serve as a platform for drug delivery. ACS Biomaterials Science & Engineering, 6(8), 4414-4423. doi: 10.1021/acsbiomaterials.0c00188 Gelders, G., Baekelandt, V., Van der Perren, A. (2018). Linking neuroinflammation and neurodegeneration in Parkinson’s disease. Journal of Immunology Research, 2018, 4784268. doi: 10.1155/2018/4784268 Global Burden of Disease (GBD) 2016 Neurology Collaborators. (2019). Global, regional, and national burden of neurological disorders, 1990-2016: A systematic analysis for the global burden of disease study 2016. The Lancet Neurology, 18(5), 459–480. doi: 10.1016/S1474-4422(18)30499-X Gonçalves, P. B., Sodero, A. C. R., Cordeiro, Y. (2021). Green tea epigallocatechin-3-gallate (egcg) targeting protein misfolding in drug discovery for neurodegenerative diseases. Biomolecules, 11(5), 767. doi: 10.3390/biom11050767 Hu, G., Bidel, S., Jousilahti, P., Antikainen, R., Tuomilehto, J. (2007). Coffee and tea consumption and the risk of Parkinson's disease. Movement Disorders, 22(15), 2242- 2248. doi: 10.1002/mds.21706 Iakovenko, E. V., Abramycheva, N. Y., Fedotova, E. Y., Illarioshkin, S. N. (2020). The SNCA-rep1 polymorphic locus: association with the risk of Parkinson's disease and SNCA gene methylation. Acta Naturae, 12(2), 105–110. doi: 10.32607/actanaturae.10956 Jankovic, J., Tan, E. K. (2020). Parkinson's disease: etiopathogenesis and treatment. Journal of Neurology, Neurosurgery, and Psychiatry, 91(8), 795–808. doi: 10.1136/jnnp-2019-322338 Kalia, L. V., Lang, A. E. (2015). Parkinson's disease. The Lancet, 386(9996), 896-912. doi: 10.1016/S0140-6736(14)61393-3 Kang, K. S, Wen, Y., Yamabe, N., Fukui, M., Bishop, S. C., Zhu, B. T. (2010). Dual beneficial effects of (−)-epigallocatechin-3-gallate on levodopa methylation and hippocampal neurodegeneration: In vitro and in vivo studies. PLoS One, 5(8), e11951. doi: 10.1371/journal.pone.0011951 Karas, D., Ulrichová, J., Valentová, K. (2017). Galloylation of polyphenols alters their biological activity. Food and Chemical Toxicology, 105, 223-240. doi: 10.1016/j.fct.2017.04.021 Kochman, J., Jakubczyk, K., Antoniewicz, J., Mruk, H., Janda, K. (2020). Health benefits and chemical composition of matcha green tea: A review. Molecules (Basel, Switzerland), 26(1), 85. doi: 10.3390/molecules26010085 Lassarén, P., Lindblad, C., Frostell, A., Carpenter, K. L. H., Guilfoyle, M. R., Hutchinson, P. J. A., … Thelin, E. P. (2021). Systemic inflammation alters the neuroinflammatory response: A prospective clinical trial in traumatic brain injury. Journal of Neuroinflammation, 18(1), 221. doi: 10.1186/s12974-021-02264-2 Liang, Y., Ip, M. S. M., Mak, J. C. W. (2019). (-)-Epigallocatechin-3-gallate suppresses cigarette smoke-induced inflammation in human cardiomyocytes via ROS-mediated MAPK and NF-κB pathways. Phytomedicine, 58, 152768. doi: 10.1016/j.phymed.2018.11.028 Lorenzen, N., Nielsen, S. B., Yoshimura, Y., Vad, B. S., Andersen, C. B., Betzer, C., ... Otzen, D. E. (2014). How epigallocatechin gallate can ınhibit α-synuclein oligomer toxicity in vitro. Journal of Biological Chemistry, 289(31), 21299-21310. doi: 10.1074/jbc.M114.554667 Mandel S., Maor G., Youdim M. B. (2004). Iron and alpha-synuclein in the substantia nigra of mptp-treated mice: effect of neuroprotective drugs r-apomorphine and green tea polyphenol (−)-epigallocatechin-3-gallate. Journal of Molecular Neuroscience, 24(3), 401- 416. doi: 10.1385/JMN:24:3:401 Mehra, S., Sahay, S., Maji, S. K. (2019). α-synuclein misfolding and aggregation: implications in Parkinson’s disease pathogenesis. Biochimica et Biophysica Acta (BBA)-Proteins and Proteomics, 1867(10), 890-908. doi: 10.1016/j.bbapap.2019.03.001 Mellick, G. D., Maraganore, D. M., Silburn, P. A. (2005). Australian data and meta-analysis lend support for alpha-synuclein (NACP-Rep1) as a risk factor for Parkinson's disease. Neuroscience Letters, 375(2), 112-116. doi: 10.1016/j.neulet.2004.10.078 Miller, D. B., O’Callaghan, J. P. (2015). Biomarkers of Parkinson’s disease: present and future. Metabolism, 64(3), S40-S46. doi: 10.1016/j.metabol.2014.10.030 Musial, C., Kuban-Jankowska, A., Gorska-Ponikowska, M. (2020). Beneficial properties of green tea catechins. International Journal of Molecular Sciences, 21(5), 1744. doi: 10.3390/ijms21051744 Niemann, N., Jankovic, J. (2019). Juvenile parkinsonism: differential diagnosis, genetics, and treatment. Parkinsonism & Related Disorders, 67, 74-89. doi: 10.1016/j.parkreldis.2019.06.025 Ntamo, Y., Jack, B., Ziqubu, K., Mazibuko-Mbeje, S. E., Nkambule, B. B., Nyambuya, T. M., … Dludla, P. V. (2024). Epigallocatechin gallate as a nutraceutical to potentially target the metabolic syndrome: novel insights into therapeutic effects beyond its antioxidant and anti-inflammatory properties. Critical Reviews In Food Science and Nutrition, 64(1), 87–109. doi: 10.1080/10408398.2022.2104805 Obeso, J. A, Stamelou, M., Goetz, C. G., Poewe, W., Lang, A. E., Weintraub, D., … Stoessl, A. J. (2017). Past, present, and future of Parkinson's disease: A special essay on the 200th anniversary of the shaking palsy. Movement Disorders: Official Journal of the Movement Disorder Society, 32(9), 1264–1310. doi: 10.1002/mds.27115 Olguín, H. J, Guzmán, D. C, García, E. H., Mejía, G. B. (2016). The role of dopamine and its dysfunction as a consequence of oxidative stress. Oxidative Medicine and Cellular Longevity, 2016, 1-13. doi: 10.1155/2016/9730467 Ouyang, J., Zhu, K., Liu, Z., Huang, J. (2020). Prooxidant effects of epigallocatechin-3-gallate in health benefits and potential adverse effect. Oxidative Medicine and Cellular Longevity, 2020, 9723686. doi: 10.1155/2020/9723686. Pękal, A., Dróżdż, P., Biesaga, M., Pyrzynska, K. (2011). Evaluation of the antioxidant properties of fruit and flavoured black teas. European Journal of Nutrition, 50(8), 681–688. doi: 10.1007/s00394-011-0179-2 Perdices, L., Fuentes-Broto, L., Segura, F., Cavero, A., Insa-Sánchez, G., Sánchez-Cano, A. I., ... Pinilla, I. (2022). Systemic epigallocatechin gallate protects against retinal degeneration and hepatic oxidative stress in the P23H-1 rat. Neural Regeneration Research, 17(3), 625-631. doi: 10.4103/1673-5374.320990 Peterson, L. J., Flood, P. M. (2012). Oxidative stress and microglial cells in Parkinson's disease. Mediators of Inflammation, 2012, 401264. doi: 10.1155/2012/401264 Pfeiffer, R. F. (2016). Non-motor symptoms in Parkinson's disease. Parkinsonism & Related Disorders, 22, S119-S122. doi: 10.1016/j.parkreldis.2015.09.004 Postuma, R. B, Berg, D., Stern, M., Poewe, W., Olanow, C. W., Oertel, W., … Deuschl, G. (2015). MDS clinical diagnostic criteria for Parkinson's disease. Movement Disorders: Official Journal of the Movement Disorder Society, 30(12), 1591–1601. doi: 10.1002/mds.26424 Rahmani, A. H., Al Shabrmi, F. M., Allemailem, K. S., Aly, S. M., Khan, M. A. (2015). Implications of green tea and its constituents in the prevention of cancer via the modulation of cell signalling pathway. Biomed Research International, 2015, 925640. doi: 10.1155/2015/925640 Saeed, A. A., Genové, G., Li, T., Lütjohann, D., Olin, M., Mast, N. ... Björkhem, I. (2014). Effects of a disrupted blood-brain barrier on cholesterol homeostasis in the brain. Journal of Biological Chemistry, 289(34), 23712-23722. doi: 10.1074/jbc.M114.556159 Sanchez-Guajardo, V., Tentillier, N., Romero-Ramos, M. (2015). The relation between α-synuclein and microglia in Parkinson’s disease: recent developments. Neuroscience, 302, 47-58. doi: 10.1016/j.neuroscience.2015.02.008 Seppi, K., Ray Chaudhuri, K., Coelho, M., Fox, S. H., Katzenschlager, R., Perez Lloret, S., … the collaborators of the Parkinson's Disease Update on Non-Motor Symptoms Study Group on behalf of the Movement Disorders Society Evidence-Based Medicine Committee. (2019). Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review. Movement Disorders: Official Journal of the Movement Disorder Society, 34(2), 180–198. doi: 10.1002/mds.27602 Shu, L., Zhang, Y., Sun, Q., Pan, H., Guo, J., Tang, B. (2018). SNCA REP-1 and Parkinson’s disease. Neuroscience Letters, 682, 79-84. doi: 10.1016/j.neulet.2018.05.043 Singh, N. A., Mandal, A. K., Khan, Z. A. (2016). Potential neuroprotective properties of epigallocatechin-3-gallate (EGCG). Nutrition Journal, 15(1), 60. doi: 10.1186/s12937-016-0179-4 Suzuki, T., Pervin, M., Goto, S., Isemura, M., Nakamura, Y. (2016). Beneficial effects of tea and the green tea catechin epigallocatechin-3-gallate on obesity. Molecules, 21(10), 1305. doi: 10.3390/molecules21101305 Tseng, H. C., Wang, M. H., Chang, K. C., Soung, H. S., Fang, C.H, Lin, Y. W., … Tsai, C. C. (2020). Protective effect of (-) epigallocatechin-3-gallate on rotenone-induced parkinsonism-like symptoms in rats. Neurotoxicity Research, 37(3), 669–682. doi: 10.1007/s12640-019-00143-6 Umeno, A., Biju, V., Yoshida, Y. (2017). In vivo ROS production and use of oxidative stress-derived biomarkers to detect the onset of diseases such as alzheimer’s disease, Parkinson’s disease, and diabetes. Free Radical Research, 51(4), 413-427. doi: 10.1080/10715762.2017.1315114 World Health Organization (WHO). (2023). Parkinson disease. Erişim Tarihi 02.10.2023, https://www.who.int/news-room/fact sheets/detail/parkinson-disease. Yang, Y., Qin, Y. J., Yip, Y. W., Chan, K. P., Chu, K. O., Chu, W. K., ... Chan, S. O. (2016). Green tea catechins are potent anti-oxidants that ameliorate sodium iodate-induced retinal degeneration in rats. Scientific Reports, 6(1), 29546. doi: 10.1038/srep29546 Yuan, H., Li, Y., Ling, F., Guan, Y., Zhang, D., Zhu, Q., … Niu, Y. (2020). The phytochemical epigallocatechin gallate prolongs the lifespan by improving lipid metabolism, reducing inflammation and oxidative stress in high-fat diet-fed obese rats. Aging Cell, 19(9), e13199. doi: 10.1111/acel.13199 Zhao, L., Liu, S., Xu, J., Li, W., Duan, G., Wang, H., ... Zhou, R. (2017). A new molecular mechanism underlying the egcg-mediated autophagic modulation of afp in hepg2 cells. Cell Death & Disease, 8(11), e3160. doi: 10.1038/cddis.2017.563 Zwolak, I. (2021). Epigallocatechin gallate for management of heavy metal-induced oxidative stress: mechanisms of action, efficacy, and concerns. International Journal of Molecular Sciences, 22(8), 4027. doi: 10.3390/ijms22084027